Immuneering (IMRX) EBITDA Margin (2020 - 2022)
Immuneering (IMRX) posted quarterly EBITDA Margin of 3073627.91% for Q4 2022, down 306776489.0% year-over-year from N/an in Q4 2021, and down 8844.84% quarter-over-quarter from 34362.04% in Q3 2022.
Immuneering (IMRX) EBITDA Margin (2020 - 2022) Analysis & Trends
Immuneering's EBITDA Margin history runs 3 years deep, the most recent figure standing at 3073627.91% for Q4 2022.
- In Q4 2022, EBITDA Margin fell 306776489.0% year-over-year to 3073627.91%; the TTM figure through Sep 2023 stood at 12328770.77% (down 1231911324.0% YoY), while the FY2022 annual figure was 16325.77%, down 1469661.0% from the prior year.
- EBITDA Margin for Q4 2022 stood at 3073627.91%, down from 34362.04% in the prior quarter.
- The five-year high for EBITDA Margin was 644.66% in Q3 2020, with the low at 3073627.91% in Q4 2022.
- The 3-year median for EBITDA Margin is 1772.01% (2021), against an average of 285392.02%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin plunged 46060 bps in 2021, then slumped 306776489 bps in 2022.
- Immuneering's EBITDA Margin stood at 877.56% in 2020, then plunged by 568 bps to 5863.02% in 2021, then tumbled by 52324 bps to 3073627.91% in 2022.
- Business Quant data shows IMRX's EBITDA Margin at 3073627.91% in Q4 2022, 34362.04% in Q3 2022, and 12334.43% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -3,073,627.91% |
| Sep 30, 2022 | -34,362.04% |
| Jun 30, 2022 | -12,334.43% |
| Mar 31, 2022 | -7,036.37% |
| Dec 31, 2021 | -5,863.02% |
| Sep 30, 2021 | -1,772.01% |
| Jun 30, 2021 | -1,210.67% |
| Mar 31, 2021 | -833.47% |
| Dec 31, 2020 | -877.56% |
| Sep 30, 2020 | -644.66% |
| Jun 30, 2020 | -750.08% |